"难道只有人工智能、机器人、新材料才算'硬科技'吗？我们从事的是关乎人类健康的生命科学领域， 这同样是硬核科技。"近日，澳斯康生物创始人、董事长兼总裁罗顺透露，公司正在积极筹备港股上 市，成为又一家冲刺港交所"特专科技"上市的生物制造企业。 从2011年回国创立中国首家无血清细胞培养基企业，到如今建成覆盖培养基、CRDMO（合同研发生产 组织）的全产业链平台，罗顺带领澳斯康生物在过去十余年间，见证并推动了中国生物制药关键原材料 从严重依赖进口到自主可控的进程。 "我刚回国时，国内几乎所有生物制药企业用的都是进口培养基。"罗顺直言，"价格高昂是其一，更重 要的是供应链存在风险。" 罗顺的工作经历为他打破这一垄断提供了可能。他曾在美国三大培养基公司之一的默克密理博（Merck Millipore）担任工业化细胞培养基业务的研发负责人，深谙培养基研发与产业化的核心技术。 而此次瞄准港股上市，也意味着这家已实现盈利的"隐形冠军"，正希望借助资本市场，进一步强化其在 生物制药产业化环节的硬核实力与平台价值。 破局：攻克生物制药的"底座"市场 "生物医药是国家战略支柱产业，但过去很多关键环节，比如细胞培养基，在2021年 ...

"2011年回国创业时，中国生物制药明显落后于印度，尤其当时印度的生物类似药产业已走在前列，但 我和很多海外回归的朋友一致认为，依托中国产业根基与政策支持，要不了多久，我们一定会超过印 度。" 澳斯康生物创始人罗顺博士回忆道。 今天，这样的预判变成了现实。中国的创新药经历了十余年的蓬勃发展之后，在研发管线、上市新药数 量等方面已经远远超过印度，甚至在ADC等领域已经逐渐赶超美国制药产业。 澳斯康等一大批生物制药产业链企业，在过去十年间与中国制药产业共同成长，成为创新生态中的重要 组成部分。 与中国制药产业共进 2011年，罗顺从美国回到中国创业。 罗顺是第一代国家资金资助出国留学的大学生，他在美国弗吉尼亚理工大学获得分子免疫学博士，也是 美国哈佛大学医学院Dana-Farber癌症研究所博士后。回国创业之前，罗顺曾在多家跨国药企担任重要 研发职务。 当时中国制药行业还停留在仿制药阶段，创新药板块刚刚起步，印度制药行业都走在中国前面。 罗顺回国后，在兰州建立了健顺生物科技。在此之前，中国还没有符合医药政策和国际标准的无血清细 胞培养基，市场所需产品完全依赖进口。 "2015年之前，我们制药行业的法律法规相对比较 ...

Core Viewpoint - Angel Yeast has demonstrated steady growth in performance through increased brand investment and international market expansion, achieving significant revenue and profit increases in the first half of 2025 [1][2][3]. Group 1: Financial Performance - In the first half of 2025, Angel Yeast reported revenue of approximately 7.9 billion yuan, a year-on-year increase of 10.1% [1][2]. - The net profit attributable to shareholders reached 799 million yuan, reflecting a year-on-year growth of 15.7% [1][2]. Group 2: Brand and Market Position - Angel Yeast is the second-largest yeast company globally, with a brand value exceeding 20 billion yuan and a brand strength score of 914, leading the domestic food processing sector [2]. - The company has a total yeast production capacity exceeding 450,000 tons, holding a 55% market share in China and over 20% globally, exporting to more than 170 countries and regions [2]. Group 3: International Expansion - In Q2 2025, overseas revenue grew by 22.3% year-on-year, accounting for 28.4% of total revenue [3]. - The company’s international revenue reached 5.712 billion yuan in 2024, representing 37.6% of total revenue, with a notable increase of 3.193 billion yuan over the past five years [3]. Group 4: Product Development and Innovation - Angel Yeast is actively expanding its product boundaries, with yeast protein exported to over 40 countries for use in various food applications [4]. - The company is investing in biotechnology, with projects including a 230 million yuan investment in serum-free cell culture technology and a 502 million yuan investment in a biomanufacturing center [5].

Company Performance - Anqijiao Yeast reported a revenue of 7.899 billion yuan for the first half of 2025, representing a year-on-year growth of 10.10% [1] - The net profit attributable to the parent company reached 799 million yuan, with a year-on-year increase of 15.66% [1] - The fermentation output for the first half of the year was 228,000 tons, showing an 11.8% increase compared to the previous year [1] Production and R&D - The company has a total yeast production capacity exceeding 450,000 tons, holding a 55% market share in China and over 20% globally [1] - R&D expenses for the first half of the year amounted to 306 million yuan, reflecting a 3.65% increase year-on-year [1] - Key products such as high-sugar yeast and low-sugar yeast have seen significant improvements in key performance indicators due to process optimization [1] Industry Context - The global yeast production capacity exceeds 2.1 million tons, with the top three companies (Lesaffre, Anqijiao, and Angel Yeast) accounting for over 70% of the market share [2] - The yeast industry is experiencing increased concentration and intensified competition, with international peers adjusting their global strategies [2] Cost Management - Molasses accounts for nearly 60% of yeast production costs, significantly impacting profitability; the company has previously replaced part of the molasses with hydrolyzed sugar [2] - Anqijiao Yeast plans to continuously monitor raw material price fluctuations and optimize its pricing prediction mechanisms [2] Strategic Initiatives - The company announced plans to acquire a 55% stake in Shengtong Sugar Industry for 506 million yuan, aimed at enhancing its sugar segment and downstream business [2] - Anqijiao Yeast currently operates four hydrolyzed sugar production lines with a total capacity of 600,000 tons, with additional production lines under construction [2]